“Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study”. SKIN The Journal of Cutaneous Medicine 2, no. S1 (February 23, 2018): S45. Accessed March 9, 2026. https://skin.dermsquared.com/skin/article/view/301.